Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction.

ABSTRACT:

Objective

This study aimed to evaluate the effect of sacubitril-valsartan (SV) on central apneas (CA) and obstructive apneas (OA) in patients with heart failure with reduced ejection fraction (HFrEF).

Methods

In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.

Results

Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to

SUBMITTER: Wang Y 

PROVIDER: S-EPMC9992232 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature